Voices
Fadi Haddad: A Pooled Analysis of Dasatinib 50 mg/Day in Frontline CML
Fadi Haddad/mdanderson.org

Fadi Haddad: A Pooled Analysis of Dasatinib 50 mg/Day in Frontline CML

Fadi Haddad, Assistant Professor at The University of Texas MD Anderson Cancer Center, shared a post on LinkedIn:

“Just out, a pooled analysis of dasatinib 50 mg/day in frontline CML confirming the safety and efficacy of the lower dose.”

Title: Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis

Authors: Fadi G. Haddad, Elias Jabbour, Koji Sasaki, Samuel Black, Jonathan Michael Savoy, Yesid Alvarado, Gautam Borthakur, Naveen Pemmaraju, Musa Yilmaz, Sara Delasalla, Ghayas C. Issa and Hagop Kantarjian.

Read The Article

Listen to the AI Transcribtion

Fadi Haddad

Other articles featuring Fadi Haddad on OncoDaily.

cancer CML Dasatinib Elias Jabbour Fadi G. Haddad Fadi Haddad Gautam Borthakur Ghayas C. Issa Hagop Kantarjian Jonathan Michael Savoy Koji Sasaki MD Anderson MD Anderson Cancer Center Musa Yilmaz Naveen Pemmaraju OncoDaily Oncology Samuel Black Sara Delasalla University of Texas Yesid Alvarado